Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
MLYS Stock Chart & Stats
$28.51
-$0.99(-7.63%)
At close: 4:00 PM EST
$28.51
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$9.69 - $47.65
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.00M
Market Cap
$2.28B
Enterprise Value$1.69B
Total Cash (Recent Filing)$217.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding79,139,950
10 Day Avg. Volume935,516
30 Day Avg. Volume1,000,828
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-3.59
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.69K
Enterprise Value/Ebitda-9.39
Forecast
1Y Price Target
$52.00Price Target Upside82.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.23
Revenue Forecast (FY)$3.30M
Bulls Say, Bears Say
Bulls Say
Consistent Subgroup EfficacySubgroup analyses indicating meaningful blood pressure reductions across age, race, sex, body mass, and different background therapies suggest broad applicability among diverse patient populations.
Key Opinion Leader EndorsementA leading cardiology key opinion leader judged lorundrostat comparable to AstraZeneca's baxdrostat on major clinical factors, bolstering clinician confidence in the drug's clinical profile.
Regulatory FilingNew drug application for lorundrostat, supported by positive pivotal data in uncontrolled and resistant hypertension, could enable regulatory approval and a commercial launch.
Bears Say
Labeling And Access RiskPotential restrictive labeling or payer access decisions could limit patient access and diminish commercial uptake despite favorable clinical trial results.
Regulatory CompetitionA competing aldosterone synthase inhibitor from a large pharmaceutical company advancing through regulatory review could intensify competition and pressure market share and pricing for lorundrostat.
Safety And Pharmacology UncertaintiesLingering uncertainties about comparative efficacy, risk of high potassium events, and drug half-life could constrain prescriber preference for lorundrostat relative to alternatives.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $9.69 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $2.28B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 12 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.613 by $0.093.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 79,139,950 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.613. Following the earnings report the stock price went up 5.865%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (82.39% Upside)
$52.00 (82.39% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 697.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
190.02%
12-Months-Change
Fundamentals
Return on Equity
-42.14%
Trailing 12-Months
Asset Growth
123.65%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including successful clinical trial outcomes and a strong financial position, with sufficient funds to support operations into 2028. The company is progressing well towards NDA submission. However, there were concerns regarding data imputation and increased G&A expenses. Overall, the positive aspects outweigh the challenges.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$52.00
▲(82.39% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Apellis Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Centessa Pharmaceuticals
―
Ownership Overview
Currently, No data available
---